Abstract

e16045 Background: Results of clinical trials have shown that the presence of visceral disease does not preclude clinical benefit from abiraterone (AA) in metastatic castration-resistant prostate c...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study.
Darren M.C Poon ... Tim W Chan
Prostate international | VOL. 6
Darren M.C Poon, et. al.Darren M.C Poon ... Tim W Chan
18 Aug 2017
Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Darren M C Poon ... Henry Sze
BMC Urology | VOL. 16
Darren M C Poon, et. al.Darren M C Poon ... Henry Sze
22 Mar 2016
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Yujiro Ueda ... Nobuaki Matsubara
Japanese Journal of Clinical Oncology | VOL. 45
Yujiro Ueda, et. al.Yujiro Ueda ... Nobuaki Matsubara
15 May 2015
Application of abiraterone acetate (AA) in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients who did not fulfil the patient inclusion criteria in the COU-AA-302 study.
Darren M C Poon ... T.W Chan
Journal of Clinical Oncology | VOL. 34
Darren M C Poon, et. al.Darren M C Poon ... T.W Chan
10 Jan 2016
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Three Days Was Enough.
Teresa Hagan Thomas
Journal of Clinical Oncology | VOL. -
Teresa Hagan ThomasTeresa Hagan Thomas
09 Jul 2024
Reply to Y. Xia et al.
Sebastian Bauer ... Thomas Mühlenberg
Journal of Clinical Oncology | VOL. -
Sebastian Bauer, et. al.Sebastian Bauer ... Thomas Mühlenberg
08 Jul 2024
Comprehensive Discussions on KIT ATP-Binding Pocket/Activation Loop Mutations in Ripretinib Resistance.
Yanzhe Xia ... Xinhua Zhang
Journal of Clinical Oncology | VOL. -
Yanzhe Xia, et. al.Yanzhe Xia ... Xinhua Zhang
08 Jul 2024
Reply to A. Jain et al.
Mariana Chávez-Villa ... Roberto Hernandez-Alejandro
Journal of Clinical Oncology | VOL. -
Mariana Chávez-Villa, et. al.Mariana Chávez-Villa ... Roberto Hernandez-Alejandro
08 Jul 2024
View more papers